Toronto, July 22, 2020 – Ferring Pharmaceuticals has discontinued production of OCTOSTIM SPRAY (150 mpg DIN 02237860) for the treatment of mild and moderate hemophilia A and von Willebrand disease. The active ingredient in OCTOSTIM SPRAY is desmopressin acetate.
The stoppage in production and distribution comes at the same time as the July 14 recall of DDAVP Nasal Spray, used in other medical conditions not related to bleeding disorders. Manufacturing issues—airtightness of the vials leading to potential overdose—are reported to be the cause of the recall.
People who normally use OCTOSTIM SPRAY should contact their treatment centre for advice on alternative treatments.